J&J Awaits Final Clearance to Re-Open Suspended Tylenol Plant, $100M and Five Years Later

After suspending manufacturing at its Consumer Healthcare plant five years ago, Johnson & Johnson's McNeil says it is now awaiting final notification from the FDA before re-opening.

Following a lengthy series of recalls involving millions of product packages, McNeil had suspended manufacturing at its Fort Washington, PA location -- the drugmaker's primary Tylenol and OTC manufacturing site.

McNeil says it recently had a successful FDA inspection at the site, after spending over $100 million on plant improvements.

Read the Philly Business Journal article